Search results for "CIRRHOSIS"

showing 10 items of 964 documents

Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outs…

2021

Background ADVanced Organ Support (ADVOS) is a novel type of extracorporeal albumin dialysis and holds promise to sustain liver function and recovery of patients with acute-on-chronic liver failure (ACLF). Previously, ADVOS was tested as continuous treatment for intensive care patients with liver failure. Data related to the applicability and safety as discontinuous treatment outside of ICU is not available. Aim Evaluation of ADVOS as discontinuous treatment for patients with ACLF outside intensive care unit and comparison with a matched historic cohort. Methods and results In this retrospective study, 26 patients with ACLF and the indication for renal replacement therapy related to HRS-AK…

MalePhysiologymedicine.medical_treatmentLiver transplantationToxicologyPathology and Laboratory MedicineSeverity of Illness IndexBiochemistrylaw.inventionBlood Urea Nitrogen0302 clinical medicinelawLiver Cirrhosis AlcoholicMedicine and Health SciencesMedicineBileMultidisciplinaryLiver DiseasesQRMiddle AgedIntensive care unitBody FluidsRenal Replacement TherapyLiverCirrhosisNephrologyCreatinineMedicine030211 gastroenterology & hepatologyFemaleHemodialysisAnatomyDetoxificationResearch Articlemedicine.medical_specialtyCritical CareScienceSurgical and Invasive Medical ProceduresGastroenterology and Hepatology03 medical and health sciencesDigestive System ProceduresRenal DialysisIntensive careInternal medicineAlbuminsMedical DialysisHumansRenal replacement therapyDialysisRetrospective StudiesTransplantationbusiness.industryAcute-On-Chronic Liver FailureBiology and Life SciencesProteins030208 emergency & critical care medicineRetrospective cohort studyBilirubinOrgan TransplantationSurvival AnalysisLiver TransplantationPatient ComplianceLiver functionbusinessBiomarkersPLoS ONE
researchProduct

Recent insights into the relationship between inflammatory liver diseases and atherosclerosis.

2011

Atherosclerosis is a dynamic process in the human body. Many studies have evaluated atherosclerosis and its relationship with other systems in the body. Our perception of its pathogenesis is evolving with the introduction of new players in the game. It is no longer possible to consider the atherosclerosis as an independent process, unaffected by the liver and its function. Although several tasks performed by the liver, such as lipid metabolism, have been implicated in the pathogenesis of atherosclerosis, the role of other disorders of the liver (autoimmune diseases, viral hepatitis, and cirrhosis) are not fully understood. In this review, the most commonly encountered inflammatory liver di…

MaleRiskHepatitis B virusCirrhosisInflammationHepacivirusBiologyGeneral Biochemistry Genetics and Molecular BiologyAutoimmune DiseasesHepatitisPathogenesisFibrosisPrevalencemedicineHumansInflammationHepatitisCholestasisLiver DiseasesResearchFatty liverLipid metabolismGeneral MedicineAtherosclerosismedicine.diseasehepatitis B hepatitis C hepatitis A inflammation fatty liver atherosclerosisFibrosisFatty LiverLiverImmunologyFemalemedicine.symptomViral hepatitis
researchProduct

Sex hormones and risk of liver tumor.

2007

The liver is morphologically and functionally modulated by sex hormones. Long-term use of oral contraceptives (OCs) and anabolic androgenic steroids (AASs) can induce both benign (hemangioma, adenoma, and focal nodular hyperplasia [FNH]) and malignant (hepatocellular carcinoma [HCC]) hepatocellular tumors. Hepatic adenomas (HAs) are rare, benign neoplasms usually occurring in young women, the development and the complications of which have been related to the strength of OCs and the duration of their use. HA incidence has fallen since the introduction of pills containing smaller amounts of estrogens. FNH is a benign lesion, most commonly seen in young women, which is thought to represent a …

MaleRiskmedicine.medical_specialtyCirrhosisLiver tumorAdenomamedicine.drug_classPhysiologyBiologyGeneral Biochemistry Genetics and Molecular BiologyAndrogenAromataseHistory and Philosophy of ScienceInternal medicinemedicineHumansSex RatioHCCGonadal Steroid HormonesHepatitisGeneral NeuroscienceLiver NeoplasmsFocal nodular hyperplasiaCancermedicine.diseaseEstrogenEndocrinologyLiverReceptors EstrogenEstrogenReceptors AndrogenHepatocellular carcinomaFemaleBenign liver tumorAnnals of the New York Academy of Sciences
researchProduct

Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy.

2010

Summary. Background: Prothrombin time (PT) and the international normalized ratio (INR) are still routinely measured in patients with liver cirrhosis to ‘assess’ their bleeding risk despite the lack of correlation with the two. Thrombin generation (TG) assays are global assays of coagulation that are showing promise in assessing bleeding and thrombosis risks. Aim: To study the relationship between the INR and TG profiles in cirrhosis-induced coagulopathy. Methods: Seventy-three patients with cirrhosis were studied. All TG parameters were compared with those from a normal control group. Contact activation was prevented using corn trypsin inhibitor. TG was also assayed in the presence of Prot…

MaleRiskmedicine.medical_specialtyPathologyCirrhosisHemorrhageGastroenterologyThrombin generationLag timeFibrinolytic AgentsInternal medicinemedicineCoagulopathyHumansIn patientInternational Normalized RatioBlood CoagulationAgedbusiness.industryThrombinAnticoagulantsHematologyBlood Coagulation DisordersMiddle Agedmedicine.diseaseThrombosisFibrosisCoagulationLiverIntercellular Signaling Peptides and ProteinsFemalebusinessPeptidesProtein Cmedicine.drugProtein CJournal of thrombosis and haemostasis : JTH
researchProduct

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver …

2015

In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (…

MaleSettore MED/09 - Medicina Internaboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Infectious Diseases; Virology; Medicine (all)Hepacivirusboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Virology; Infectious DiseasesGastroenterologyIFN-based therapy; boceprevir; cirrhosis; first-generation protease inhibitors; hepatitis Cfirst-generation protease inhibitorchemistry.chemical_compoundLiver diseaseboceprevirMedicineViralChronicSettore MED/12 - Gastroenterologiaboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy; Combination; Female; Hepacivirus; Hepatitis C; Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA; Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Infectious Diseases; Virology; Medicine (all)Medicine (all)virus diseasesHepatitis CMiddle AgedViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CInfectious DiseasesTreatment OutcomeItalyHCVCombinationRNA ViralDrug Therapy CombinationFemaleViral loadHumanAdultmedicine.medical_specialtyProlineAlpha interferonInfectious DiseaseAntiviral AgentsDrug TherapyVirologyInternal medicineBoceprevirRibavirinboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis c; IFN-based therapy; adult; aged; antiviral agents; drug therapy combination; female; hepacivirus; hepatitis c chronic; humans; interferon-alpha; italy; male; middle aged; proline; RNA viral; ribavirin; spain; treatment outcome; viral load; hepatology; infectious diseases; virologyHumansDecompensationAdverse effectAgedAntiviral AgentIFN-based therapyHepaciviruHepatologybusiness.industryRibavirincirrhosisInterferon-alphaHepatitis C Chronicmedicine.diseasedigestive system diseasesboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Loadfirst-generation protease inhibitorschemistrySpainImmunologyRNAbusinesscirrhosi
researchProduct

Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study

2017

Background and Aim The universal hepatitis B vaccination for infants and 12-year-old adolescents (the latter limited to the first 12 years of application) was launched in Italy in 1991. Twenty-three years later we evaluated the impact of the vaccination campaign on the burden of HBsAg-positive chronic liver diseases (CLD). Material and Methods 513 HBsAg-positive chronic carriers referring to 16 Italian liver units were investigated and compared with HBsAg carriers enrolled in previous surveys. Results The proportion of inactive carriers decreased from 20.0% in 2001 to 3.3% in 2014, while that of cirrhotic patients increased from 22.6 to 33.2%. Regarding the age class 0–33 (fully covered by …

MaleTime FactorsCirrhosisSettore MED/09 - Medicina InternaHbv vaccination0302 clinical medicinechronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccinationMedicine030212 general & internal medicineChildAged 80 and overVaccinationMiddle AgedVaccinationInfectious DiseasesItalyLiverCarrier StateFemale030211 gastroenterology & hepatologyHbsag carrierAdultHepatitis B virusAdolescentYoung Adult03 medical and health sciencesHepatitis B ChronicChronic hepatitisVirologyHumansHBsAg-positive chronic hepatitis clinical presentationHepatitis B Vaccineschronic hepatitis BHepatitis B AntibodiesHBsAg-positive chronic hepatitisAgedHBsAg chronic carrierHBV vaccinationImmunization Programsbusiness.industrychronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; virology; infectious diseasesInfantchronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; Virology; Infectious Diseasesmedicine.diseaseVirologyCross-Sectional StudiesHBsAg chronic carriersMulticenter studyHepatitis b vaccinationHBsAg-positive chronic hepatitibusiness
researchProduct

Association Between Single Nucleotide Polymorphisms in the Cyclooxygenase-2, Tumor Necrosis Factor-α, and Vascular Endothelial Growth Factor-A Genes,…

2011

Cyclooxygenase-2 (COX-2), vascular endothelial growth factor-A (VEGF-A), and tumor necrosis factor-α (TNF-α) are mediators of inflammation and angiogenesis; all of them are produced in liver cirrhosis (LC) and in hepatocellular carcinoma (HCC). It was proposed that there is an association between single nucleotide polymorphisms (SNPs) and HCC. These allelic variants influence the transcriptional activity of these genes, and therefore the proteins levels. The VEGF-A pathway is a potential therapeutic target in HCC, and several antiangiogenic agents have entered clinical trials in HCC. We evaluated the frequency of SNPs of COX-2, TNF-α, and VEGF-A genes in patients with HCC versus LC patients…

MaleVascular Endothelial Growth Factor AHeterozygoteCarcinoma HepatocellularCirrhosisAngiogenesisSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideBiochemistryCOX-2 TNFa VEGF Hepatocellular Carcinoma SNPsGeneticsmedicineHumansneoplasmsMolecular BiologyTumor Necrosis Factor-alphaHomozygoteLiver Neoplasmsnucleotide polymorphisms cyclooxygenase-2 tumor necrosis factor-α vascular endothelial growth factor-A geneshepatocellular carcinoma.Heterozygote advantagemedicine.diseasedigestive system diseasesVascular endothelial growth factor ACyclooxygenase 2Hepatocellular carcinomaImmunologyCancer researchMolecular MedicineFemaleTumor necrosis factor alphaRestriction fragment length polymorphismBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort

2020

 In order to reduce alcohol relapse after liver transplantation (LT), the German national guidelines for waiting-list maintenance and organ allocation demand a minimum 6-month period of alcohol abstinence pre-LT, confirmed by measuring urinary ethyl glucuronide (uEtG). Between January 2015 and June 2016, uEtG was measured at least once in 339 cirrhotic patients with an indication for LT at the University Medical Center Mainz. uEtG was measured with an enzyme-linked immunosorbent assay (ELISA) screening test (cutoff value: 500 µg/L). For uEtG values ≥ 500 µg/L, liquid chromatography-mass spectrometry (LC-MS/MS) was performed as a confirmatory assay. Data were collected prospectively in a tra…

Malemedicine.medical_specialtyAlcohol DrinkingWaiting ListsUrinary systemmedicine.medical_treatmentEnzyme-Linked Immunosorbent AssayGlucuronatesLiver transplantationSensitivity and SpecificityGastroenterologyCohort Studies03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEthyl glucuronideLiver Cirrhosis AlcoholicPredictive Value of TestsTandem Mass SpectrometryInternal medicineHumansMass ScreeningMedicineProspective Studies030212 general & internal medicineProspective cohort studyMean corpuscular volumeAgedCreatinineEthanolmedicine.diagnostic_testbusiness.industryGastroenterologyMiddle AgedLiver TransplantationchemistryPredictive value of testsFemale030211 gastroenterology & hepatologybusinessBiomarkersChromatography LiquidAlcohol AbstinenceZeitschrift für Gastroenterologie
researchProduct

Carcinogenic Etheno DNA Adducts in Alcoholic Liver Disease: Correlation with Cytochrome P-4502E1 and Fibrosis.

2017

BACKGROUND One mechanism by which alcoholic liver disease (ALD) progresses is oxidative stress and the generation of reactive oxygen species, among others due to the induction of cytochrome P-4502E1 (CYP2E1). Experimental data underline the key role of CYP2E1 because ALD could be partially prevented in rats by the administration of the specific CYP2E1 inhibitor chlormethiazole. As CYP2E1 is linked to the formation of carcinogenic etheno DNA adducts in ALD patients, a causal role of alcohol-induced CYP2E1 in hepatocarcinogenesis is implicated. The purpose of this study was to investigate CYP2E1 induction in ALD, and its correlation with oxidative DNA lesions and with hepatic histology. METHO…

Malemedicine.medical_specialtyAlcoholic liver diseaseCarcinoma HepatocellularCarcinogenesisMedicine (miscellaneous)Intra-Abdominal FatToxicologymedicine.disease_causeGastroenterology03 medical and health sciences0302 clinical medicineFibrosisLiver Cirrhosis AlcoholicInternal medicineDNA adductmedicineHumansLiver Diseases AlcoholicCarcinogenInflammationDeoxyadenosinesbusiness.industryLiver NeoplasmsDeoxyguanosineCytochrome P-450 CYP2E1CYP2E1Middle Agedmedicine.diseaseFibrosisImmunohistochemistryPsychiatry and Mental healthLiver8-Hydroxy-2'-Deoxyguanosine030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleSteatosisHepatic fibrosisbusinessOxidative stressAlcoholism, clinical and experimental research
researchProduct

Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis.

2004

The liver plays a prominent role in the metabolism of asymmetric dimethyl-l-arginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase. This study was designed to determine whether plasma levels of ADMA and NO production are altered in patients with compensated and decompensated alcoholic cirrhosis.Plasma levels of l-arginine, ADMA, symmetric dimethylarginine (SDMA) and NO (nitrite plus nitrate, NOx) were measured in nine patients with compensated alcoholic cirrhosis (Child-Pugh A) and 11 patients with advanced cirrhosis (Child-Pugh B-C). Seven healthy volunteers served as controls.ADMA and NOx concentrations in decompensated cirrhosis were higher than in the compensated group a…

Malemedicine.medical_specialtyAlcoholic liver diseaseCirrhosisVasodilationArginineNitric OxideNitric oxidechemistry.chemical_compoundLiver Cirrhosis AlcoholicInternal medicineBlood plasmamedicineHumansNitriteNitritesNitratesHepatologybusiness.industryMetabolismMiddle Agedmedicine.diseaseVasodilationEndocrinologychemistryFemaleEndothelium VascularbusinessAsymmetric dimethylarginineJournal of hepatology
researchProduct